FN-C/H II is
%-HSPG isolated from B104 cells directly bound to FN-C/H II both in solid phase assays and by affinity chromatography, but failed to bind to a control peptide from this region, CSI. The binding of %-HSPG was predominantly mediated by the HS and not the core protein of the HSPG.
SDS-PAGE of iodinated
HSPG demonstrated a single 76 kDa core protein following heparitinase digestion, which migrated at 51 kDa under nonreducing conditions. Anti-HSPG antibodies recognized the 76 kDa core protein by immunoblotting, and stained the surface of rat B104 neuroblastoma cells and cells of the primary neonatal rat nervous system. These results identify a cell-surface HSPG that likely mediates neuronal cell binding interactions with FN-C/H II.
Fibronectin (FN) is an extracellular matrix (ECM) component that plays a role in several cellular processes including cellular migrations during development, metastasis, and neurite outgrowth (Furcht, 1981; Rogers et al., 1983 Rogers et al., , 1989 Boucaut et al., 1984; Hynes, 1985; Dufour et al., 1988a,b; Ruoslahti, 1988a; Sanes, 1989; Yamada, 1989; Reichardt and Tomaselli, 1991) . FN is structurally complex, with several functional domains that are represented by proteolytic fragments of FN, each of which contains multiple cell adhesion-promoting sequences. For example, a proteolytic fragment containing the arginyl-glycyl-aspartyl-serine (RGDS) cell binding sequence promotes the adhesion of several cell types, including melanoma cells and fibroblasts (Pierschbacher and Ruoslahti, 1984; Pytela et al., 1985; McCarthy et al., 1986 McCarthy et al., , 1988 as well as peripheral neurite outgrowth (Carbonetto et al., 1983; Rogers et al., 1985 Rogers et al., , 1987 Waite et al., 1987) . However, the RGD-containing fragment is a poor substratum for CNS neurite outgrowth (Rogers et al., 1985 (Rogers et al., , 1987 . In contrast, a 33 kDa proteolytic fragment containing the carboxy-terminal cell and heparin binding domain of FN effectively promotes CNS, as well as PNS, neurite outgrowth (Rogers et al., 1985 (Rogers et al., , 1987 . Additionally, the 33 kDa fragment promotes the adhesion of several other cell types, suggesting a broader biological role for this fragment (Izzard et al., 1986; McCarthy et al., 1986 McCarthy et al., , 1988 Liao et al., 1989; Visser et al., 1989; Wayner et al., 1989; Mould et al., 1990) . Previous work has established that a synthetic peptide from the 33 kDa cell and heparin binding fragment, FN-C/H II (KNNQKSEPLIGRKKT), is a particularly effective substratum for neural cells (Haugen et al., 1990 ). FN-C/H II promotes neurite outgrowth by cells of both the CNS and PNS (Haugen et al., 1992) . CNS neurons are especially responsive to IN-C/H II, both in comparison to their response to other FN synthetic peptides, and in comparison to peripheral neurite outgrowth on FN-C/H II (Haugen et al., 1992) . FN-C/H II also promotes the adhesion and spreading of rat B 104 neuroblastoma cells (Haugen et al., 1990 ) and of neural crest-derived melanoma cells Drake et al., 1992) . The neural cell receptor for FN-C/H II has not yet been identified, but previous evidence suggests a cell-surface proteoglycan (PG) as a possible candidate. First, IN-C/H II binds heparin in solid phase assays . Second, neural cell adhesion, spreading, and neurite outgrowth on FN-C/H II are significantly inhibited by the addition of soluble heparin (Haugen et al., 1990 (Haugen et al., , 1992 Drake et al., 1992) .
PCs are composed of a core protein, to which are attached Hook et al., 1984; Gallagher et al., 1986; Ruoslahti, 1988b; Gallagher, 1989) . Several different PGs exist in the nervous system, suggesting diverse roles in nervous system development (Matthew et al., 1985; Perris and Johansson, 1987; Hoffman et al., 1988; Margolis and Margolis, 1989; Zaremba et al., 1989; Herndon and Lander, 1990; Snow et al., 1990) . A substantial amount of literature supports a role for cell-surface PGs as receptors for ECM components such as FN (Laterra et al., 1983; Rapraeger and Bemfield, 1983; Koda et al., 1985; Culp et al., 1986 Culp et al., , 1989 Woods et al., 1986; LeBaron et al., 1988 LeBaron et al., , 1989 Mugnai et al., 1988; Saunders and Bemfield, 1988; Vallen et al., 1988; Kaesberg et al., 1989; Gallagher, 1989; Ruoslahti, 1989; Sun et al., 1989) . In particular, an isolated PG from mouse epithelial cells, syndecan, binds to the carboxy-terminal cell and heparin binding domain of PN (Saunders and Bemfield, 1988) , although a specific PG binding sequence within this region of FN has not previously been identified. In this study, we further investigated the possibility that a cell-surface PG might act as a neural receptor for FN-C/H II. Digestion of cell-surface heparin sulfate (HS) PGs (HSPGs) with heparitinase enzyme or treatment of neuroblastoma cells with anti-HSPG IgGs inhibited cell adhesion and spreading on PN-C/H II. In addition, an HSPG isolated from neuroblastoma cells bound directly to FN-C/H II. By immunofluorescence, anti-HSPG IgGs, which recognized an HSPG core protein, stained neuroblastoma cells, as well as primary cells of both the CNS and PNS. Our data identify an HSPG from neural cells as a likely receptor for FN-C/H II.
Materials and Methods
Cell culture. The neuroblastoma cell line B 104, isolated by in vivo mutagenesis and generously donated by Dr. D. Schubert (Salk Institute), expresses several neuronal characteristics, including electrical excitability, neurotransmitter synthesis, and net&e-like process formation (Schubert et al., 1974) . Cells were maintained free of mycoplasma contamination and cultured as described previously (Haugen et al., 1990) .
Peptide preparation. Human plasma FN was purified as a byproduct of factor VIII production by sequential ion-exchange and gelatin affinity chromatography as previously described (McCarthy et al., 1986) . A 2 min trypsin digest followed by a cathepsin D digest produced the 75 kDa, 33 kDa, and 66 kDa fragments as described (McCarthy et al., 1986 ; see Fig. 1 for fragment location).
Peptides were synthesized at the University of Minnesota Microchemical Facility using a Beckman System 990 peptide synthesizer. The procedures used were based on the Merrifield solid phase system (Stewart and Young, 1984) . Lyophilized crude peptides were purified, and their nuritv and comnosition were verified bv HPLC analvsis as described (McCarthy et al., 1988 described (McCarthy et al., , 1990 Chelberg et al., 1989; -Haugen et al., 1990) . All peptides were synthesized with a tyrosine residue at the carboxy-terminal end to facilitate radioiodination of the peptides. The FN peptides specifically used for this study were IN-C/H II, representing residues 1946-l 960 (KNNQKSEPLIGRKKT), and CS 1, from the differentially spliced 111~s region found in FN A-chains and having a primary sequence of DELPQLVTLPHPNLHGPEILDVPST (Humphries et al., 1987) . The sequences shown use the single letter amino acid code (K = lysine, R = arginine, H = histidine, E = glutamic acid, D = aspartic acid, Q = glutamine, N = asparagine, P = proline, G = glycine, S = serine, T = threonine, V = valine, I = isoleucine, L = leucine, Y = tyrosine). The location of synthetic peptides is shown in Figure 1 .
Synthetic peptides were chemically conjugated to ovalbumin (OA) using I-ethyl-3(3-dimethylaminopropyl)-carbodiimide hydrochloride (Sigma) as described, based on the procedure of Bauminger and Wilchek (1980; Humphries et al., 1987; Haugen et al., 1990; McCarthy et al., 1990) .
Enzyme and antibody inhibition assays. Cell adhesion assays were performed as described previously (Haugen et al., 1990) . To evaluate the inhibition of cell adhesion with polyclonal anti-HSPG antibodies, cells were preincubated with various concentrations of antibody for 20 min and then plated directly into the wells precoated with substrata that promoted half-maximal cell adhesion, and allowed to attach for 20-30 min. For heparitinase or chondroitinase ABC treatment, released cells were washed in F12Hepes medium (Haugen et al., 1990) and incubated with or without the indicated concentration of heparitinase or chondroitinase ABC (Sigma) for 15 min at 37°C. Cells were then plated to coated substrata and incubated for 20-30 min.
Proteoglycan purijicution. Subconfluent cultures of 35S-sulfat*labeled B104 rat neuroblastoma cells were incubated in detergent extraction buffer [O. 15 M NaCl, 10 mM Tris, 5 mM MgCl,, 2 mM EDTA, 0.24 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1% Triton X-100, pH 7.21 at 37°C for 15 min. The detergent extracts were centrifuged at 1500 rpm for 5 min to remove insoluble material and then dialyzed in small pore dialysis tubing (MW cutoff, 3500) against acetate buffer (0.5 M Na acetate. 0.1 M Na sulfate. 10 mM EDTA, 0.1 M PMSF. 10 rn; 6-aminohexanoic acid, 1% Tritoh X-100, pH 6.8) to remove unincorporated ?S-sulfate (Oegema et al., 1979) . Next, the extracts were dialyzed into DEAE buffer (0.15 M Tris, 6.0 M urea, 0.1 M NaCl, 0.01 M EDTA, 0.0 1 M 6-aminohexanoic acid, 0.2% Triton X-100, or 0.2% CHAPS, 0.1 M PMSF, pH 7.0) and applied to a high-performance liquid chromatography (HPLC Beckman model 1lOA) 7.5 x 75 mm TSK DEAE 5PW anion-exchange column (Bio-Rad, Richmond, CA). Samples were applied at a flow rate of 1 ml/min, and proteins were eluted with a linear gradient from 0.1 M to 0.8 M NaCl (Klein et al., 1989) . Fractions of 1 ml each were collected and sampled for the presence of IS-sulfate by liquid scintillation (Beckman LS 3801). The salt gradient was monitored by conductivity measurements using a Radiometer conductivity meter (model CDM 83). Comparisons were made to standards of known NaCl concentration in DEAE buffer to calculate the actual salt concentrations of the fractions. To ensure adequate separation of 35S-proteoglycans, HPLC-DEAE chromatographic peaks were pooled and each rechromatographed on the same column prior to further characterization. The percentage recovery from the HPLC-DEAE columns was 90-95%. Samples were dialyzed into water and lyophilized. Aliquots were stored at -80°C and used as indicated. equilibrated in 4 M guanidine, 10 mM T&pH 7.2, 1% Triton X-100 buffer, was used for purification of 35S-sulfate HSPGs. Estimates of the HSPG and HS molecular weights were made by gel filtration on SeGel filtration on Sepharose CL4B (Sigma) columns (0.9 x 110 cm) 0.2% CHAPS, and then batch eluted in 1.0 M NaCl DEAE buffer. 35S-molecules were precipitated with 4 vol of ethanol at 4°C overnight and (M,, 2.6 x 106) and chondroitin 4-sulfate OM,, 20,000) were used as then centrifugated at 5500 rpm for 30 min. The precipitate was resuspended in the original guanidine extraction buffer, and solid CsCl was markers. HSPG bands were excised and used to immunize New Zealand added (0.44 gm CsCl/gm extract) at 40,000 rpm and 4°C for 60 hr. The gradients were separated into a bottom two-fifths (high buoyant density) White rabbits. Immunization was performed bv mixing equal volume and a top three-fifths (low buoyant density) fraction (Oegema et al., 1979) . The high buoyant density fraction (r = 1.44) was dialyzed into DEAE buffer with 0.2% Triton X-100 and analyzed by HPLC-DEAE ion-exchange column chromatography (see above). HSPG eluted as a single peak (0.32 M NaCI) by HPLC-DEAE and was dialyzed into water with 0.5 mM PMSF and lyophilized. Lyophilized tumor-extracted HSPG was then electrophoresed in a preparative 0.6% agarose, 1.8% polyacrylamide gel (Klein et al., 1986) and stained with 0.2% toluidine blue in 0.1 N acetic acid to visualize the bands. A rat chondrosarcoma CSPG pharose CL6B (Sigma) columns (0.9 x 110 cm)-equilibrated in 0.5 M sodium acetate. 0.2% CHAPS. 0.02% Na azide buffer. Columns were eluted with a flow rate of 3 mihr (Klein et al., 1986) . Fractions of 1 ml were collected with a 85-95% recovery of radioactivity from these columns. Rat chondrosarcoma chondroitin sulfate (CS) PG (CSPG; Oegema et al., 1975 ) associated with 4% hyaluronic acid and glucuronolactone were used to mark the column void (I',) and total (V,) volumes, respectively.
)S-GAGS were released from proteoglycan protein cores by alkaline ,&elimination in 0.05 N NaOH containing 1 M NaBH, over 24 hr at 45°C. The reaction mixture was neutralized by the dropwise addition ofacetic acid and desalted on Sephadex G-50 (Sigma) columns (Oegema et al., 1979) . 35S-GAGs were recovered from the column V0 with less than 5% of alkali-treated material included in the column. The HS and CS contents of 35S-GAG samples were determined by sequential nitrous acid deaminative cleavage and chondroitinase ABC treatment as previously described (Brown et al., 198 1) . Detergent-extracted 35S-macromolkcules resistant to the effects of nitrous acid and chondroitinase ABC digestion were considered "J5S-alvcooroteins" (Brown et al., 198 1) . and this population never exceeded-2% of any extract examined. " Sepharose CL4B-purified HSPG that had been eluted from an FN-C/H II-OA affinity column was radioiodinated using Nalz51 and an iodobead (Pierce, Rockford, IL) in a 50 mM Tris, pH 7.0,0.2% CHAPS buffer. After a 15 min incubation, the reaction mixture was applied to a 0.5 ml DEAE-Spetra/Gel column (Spectrum, Los Angelos, CA) equilibrated in DEAE buffer. Free NalZ51 was removed by washing the column with 0.1 M NaCl DEAE buffer. The ?-HSPGs were eluted from the column in DEAE buffer containing 1 .O M NaCl. The l*SI-labeled HSPGs were dialyzed into deionized water with 0.1 mM PMSF and frozen at -80°C. Radioactivity was quantitated in a gamma counter (TM Analytic, Gamma Trac 1193). Aliquots were treated with heparitinase or chondroitinase ABC (Siama and Seikanaku America Inc.. Rockville. MD) in 50 mM Tris, pH 7.0, 10 mM C'a acetate, 1 mM PMSF, 0.036 mM pepstatin, and 10 mM NEM for 4 hr at 37°C and analyzed by 7.5% SDS gel electrophoresis under nonreducing conditions . Gels were dried under vacuum and viewed by autoradiography using Kodak XAR5 film.
Peptideafinity chromatography. OA-peptide conjugates were coupled to Affigel-10 beads (Bio-Rad) following packaging direction (1 mg OA! ml gel). Columns of 2-3 ml bed volume were made and equilibrated in 50 mM Tris, pH 7.0,0.2% CHAPS, 200 mM NaCl, 1 mM PMSF, 1 mM CaCl,, 1 mM MgCl,, and 0.01 M 6-aminohexanoic acid (column buffer). Purified ?S-HSPG was incubated for 4 hr on an OA-OA control column, and the unbound portion was incubated on an IN-C/H II-OA or CS l-OA column at 4°C overnight. ?S-HSPG columns were eluted with a linear NaCl salt gradient (0.2-l .O M) in column buffer at a flow rate of 60 ml/hr, and 1 ml fractions were collected.
Antibody preparation. K1735 M4 tumor cells were injected into the lea flanks of C57B16 x C3HHeN Fl mice. Ten uercent of the tumors w&e metabolically radiolabeled in viva by intraperitoneal injection of ?S-sulfate 24 hr prior to tumor excision. Excised tumors were extracted overnight in 4 M guanidine, 2% Triton X-100, 0.1 M NaCl, 0.5 mM PMSF, 0.1 M 6-aminohexanoic acid, 10 mM EDTA, and 1 mg/ml benzamidine at 4°C. The extract was centifuged at 5500 rpm for 30 min at 4°C to pellet insoluble material, and the supematant was dialyzed into 0.1 M NaCl DEAE buffer containing 0.2% Triton X-100. The extract was bound to DEAE overnight, washed with DEAE buffer containing of excised HSPG gel with complete Freund's adjuvant and injecting mixture into hind legs of rabbits. Subsequent biweekly boosts of HSPG and incomplete Freund's adjuvant mixture were injected. Sera were collected 7-10 d after the sixth immunization and tested by Western blot from agarose-polyacylamide gel transfer. IgG was purified from Dooled immune sera as nreviouslv described (Skubitz et al.. 1988 ) and adsorbedon FN, type'IV collagen, and laminin affinity columns to remove any potential cross-reacting antibodies to these ECM components.
Immunoblotting. Iodinated proteoglycan, which had been purified as described, was separated by SDS-PAGE and blotted onto Immobilon-P (Millipore) filter paper in 0.02 M Tris, 0.15 M glycine, 20% methanol at 75 V for 90 min. Blots were blocked in Tris-buffered saline (TBS), 5% Blotto (Carnation dried milk), and 1% normal goat serum for 16 hr. Blots were washed twice in TBS and incubated with anti-HSPG IgGs diluted 1:50 in Tween-TBS (TTBS), 1% Blotto for 2 hr. Following this, blots were washed twice in TTBS and incubated with peroxidase-goat anti-rabbit IgG diluted 1:250 in TTBS, 1% Blotto for 2 hr. Blots were washed twice more in TTBS and then once in PBS. Immunoreactivity was visualized by incubation with 0.25 mg/ml diaminobenzadine and 0.02% of a 30% H,O, solution in PBS.
Zmmunofluorescence. Spinal cords and dorsal root ganglia (DRG) were dissected from neonatal (postnatal day 1) rats, incubated in 0.25% trypsin for 20 min, and dissociated by mild trituration. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; GIBCO Laboratories, Grand Island, NY) containing 10% fetal bovine serum (FBS) and 5% horse serum (Hyclone, Logan, UT). B104 rat neuroblastoma cells were cultured in DMEM containing 7.5% calf serum and 2.5% FBS. Cells were cultured 24-48 hr on glass coverslins, which had been prepared by coating with 0.5 mg/ml pilyomithine (Sigma) followed by 1 FM FN-C/H II-OA, and then fixed with 4% paraformaldehyde in PBS for 20 min at room temperature, rinsed, and incubated in 1 mg/ml NaBH,. Coverslips were blocked in soak solution (PBS containing 5 mg/ml BSA) for 15-30 min. Primary antibodies were diluted in soak, added to the coverslips, and incubated for 1 hr at room temperature. Except for the rabbit anti-HSPG IgG (described above), the primary monoclonal antibodies used in this study were generated in mouse and directed against glial tibrillary acidic protein (GFAP; Biogenex Labs, Dublin. CA). SlOO (Chemicon. El Seaundo. CA). aalactocerebroside (a generous 'gift of Dr. Barbara'Ranscht [Ranscht 'ei al., 19821 to Dr. Steve McLoon [University of Minnesota]), and neuron-specific fi-tubulin (Tull, a generous gift of Dr. Tony Frankfurter, University of Virginia, Charlottesville). Coverslips were washed, then incubated for 1 hr with rhodamine-or fluorescein-conjugated goat anti-rabbit IgG (1: 250) or goat anti-mouse IgG (1:200) (Cooper Biomedical, Malvem, PA) (Letoumeau and Shattuck, 1989) . For tetanus toxin staining, fixed cells were incubated in 5 kg/ml of tetanus toxin C fragment (TTX-C; LIST Biological Laboratories, Campbell, CA), followed by goat anti-TTX-C and rhodamine-swine anti-goat (Accurate Chem., Westbury, NY). The coverslips were washed and mounted with a polyvinyl alcohol solution to slides. Cells were observed by fluorescence microscopy and photographed for 15-30 set on hypersensitized Tri-X Pan 35 mm film with a Nikon microscope using a 63 x planapochromat lens. Alternatively, cells were examined with a MRC-500 Confocal Imaging System (BioRad Microscience, Cambridge, MA) mounted on an Olympus BH-2 microscope equipped for epifluorescence as described by Brelje and Sorenson (199 1). (Haugen et al., 1990 (Haugen et al., , 1992 . In order to examine initially the role of cell-surface PGs in the interactions of neural cells with FN-C/H II, we treated the cells with specific enzymes that digest the GAGS of cell-surface PGs. Heparitinase enzyme was used to remove HS, while chondroitinase ABC was used to remove CS. As a first step, cells were treated with increasing concentrations of heparitinase or chondroitinase enzyme, and then cultured on substrata coated with FN-C/H II, which had been coupled to OA as described previously (Haugen et al., 1990) . Heparitinase inhibited B104 cell adhesion and spreading in a concentration-dependent manner (Fig. 2AJ) . In sharp contrast to treatment with heparitinase, chondroitinase had no effect on B 104 cell adhesion to FN-C/H II-OA (Fig. 2,4,B) . This difference was not due to inactivity of the chondroitinase enzyme, which was able to digest bovine CS under these conditions (not shown). Further, this difference was not due to contaminating protease activity in the heparitinase enzyme, as determined by its inability to digest azoeasein (not shown). These results suggest that an HSPG, and not a CSPG, plays a role in mediating B104 cell adhesion and spreading on FN-C/H II-OA.
We next contrasted the effects of these enzymes on cell adhesion to FN-C/H II-OA and an integrin binding peptide, CS l-OA, that does not bind heparin. As noted above in Figure 2 , treatment of cells with heparitinase enzyme almost totally inhibited B104 neuroblastoma cell adhesion and spreading on substrata coated with FN-C/H II-OA (Fig. 3A,B) . In contrast to FN-C/H II-OA, treatment with heparitinase enzyme had no effect on B104 cell adhesion or spreading on substrata coated with CS I-OA (Fig. 3A,B) , indicating that heparitinase does not have nonspecific inhibitory effects on cell adhesion and spreading in general. Heparitinase also had no effect on cell viability, as assessed by trypan blue dye exclusion (not shown). As noted in Figure 2 , treatment of the cells with chondroitinase ABC differed from heparitinase in that chondroitinase had no effect on B104 cell adhesion or spreading on substrata coated with FN-C/H II-OA or CSl-OA (Fig. 3A,B) .
The FN-C/H II sequence is found within the 33 and 66 kDa cell and heparin binding fragments from FN A-and B-chains. Although treatment of B104 neuroblastoma cells with heparitinase had little effect on the number of cells that could adhere on substrata coated with the 33166 kDa fragments of FN (not shown), heparitinase decreased the area of adherent cells on the 33/66 kDa fragments (compare Fig. 4A,B) . Chondroitinase had no effect on cell spreading on the 33/66 kDa fragments (not shown). This result suggests HS on the cell surface contributes to the spreading of cells on the 33/66 kD heparin binding fragments of FN.
Since this evidence suggests that an HSPG mediates B104 cell adhesion and spreading on FN-C/H II-OA and the 33/66 kDa fragments, we used polyclonal IgGs generated against mouse melanoma HSPG to attempt to inhibit neuroblastoma interactions with FN-C/H II-OA. The anti-HSPG IgGs, which were generated against a 63 kDa core protein from Kl735 M4 mouse melanoma HSPG (Drake et al., 1992) , recognize a cell-surface HSPG on rat neuroblastoma cells (see below). Anti-HSPG IgGs almost totally inhibited B104 neuroblastoma cell adhesion to substrata coated with FN-C/H II (Fig. 5) . Anti-HSPG IgGs also partially inhibited B 104 cell adhesion to substrata coated with the 33/66 kDa cell and heparin binding fragments from FN. Anti-HSPG IgGs had little to no effect on B 104 cell adhesion to substrata coated with FN or the integrin binding peptide CS l-OA (Fig. 5) , arguing against any nonspecific inhibitory effects of the antibodies. Normal rabbit IgG had no effect on adhesion of B104 cells to these substrata (not shown).
B104 neuroblastoma cells make cell-surface HSPGs that directly bind to FN-C/H II In order to isolate and study their PGs, B104 neuroblastoma cells were metabolically labeled with 35S04, which preferentially incorporates into the sulfated GAGS of PGs. The cells were then extracted in buffer containing 1% Triton X-100. As an initial purification step, the extract was subjected to HPLC-DEAE ionexchange chromatography. This step generated two 35S-labeled peaks, 1 and 2, which eluted at 0.32 M and 0.44 M, respectively (Fig. 6A) . Nitrous acid degradation, which chemically cleaves N-sulfated HS, and chondroitinase ABC enzyme treatment, which digests CS, were used to determine the GAG content of these peaks. These results indicated that peak 1 consisted of at least 90% HSPG, while peak 2 consisted of 95% CSPG (not shown). Peak 1 was pooled as indicated by the bar in Figure  6A , and rechromatographed as above, which resulted in a single peak (Fig. 6B) . The CSPG in peak 2 was not characterized further in this study. The 35S-HSPG isolated by HPLC-DEAE was then subjected to gel filtration chromatography on Sepha- rose CL4B under dissociative conditions in 4 M guanidine and detergent, to remove any proteins that may be bound to the HSPG (not shown). The 35S-HSPG was also subjected to Sepharose CMB gel filtration chromatography, in order to estimate the size of the intact PG. Intact HSPG eluted from a Sepharose CL6B column at a K,, of 0.17 (Fig. 6C) , suggesting a molecular weight of approximately 160-l 75 kDa (Heinegard and Hascall, 1974) while alkaline borohydride-released HS eluted at a K,, of 0.42 (Fig. 6C) , suggesting a molecular weight of about 25-35 kDa (Wasteson, 197 1) . The ability of alkaline treatment to release the HS confirms that the HS was attached by an O-linkage to the PG core protein.
We examined whether isolated neuroblastoma HSPG could directly bind to FN-C/H II. First, using a solid phase binding assay, HSPG was incubated on substrata coated with increasing concentrations of FYI-C/H II-OA or the integrin binding peptide CS 1 -0A. Purified 35S-HSPG bound to substrata coated with FN-C/H II-OA in a concentration-dependent manner (Fig. 7) . In contrast, 35S-HSPG did not bind to substrata coated with CSl-OA (Fig. 7) .
Neuroblastoma HSPG also directly bound to FN-C/H II-OA by affinity chromatography. Purified 35S-HSPG was first applied to an OA-OA control column. Less than 20% of the total 35S counts bound to such a column, and the unbound portion was not able to bind to a second OA-OA column (not shown). HSPG that had not bound to OA was used to bind to FN-C/H II-OA. Greater than 85% of this 35S-HSPG bound to an FN-C/H II-OA affinity column, and was eluted with 0.27 M NaCl (Fig. 8A) . In contrast, ?S-HSPG failed to bind to a CSl-OA affinity column to any extent beyond the level of binding to OA (not shown). Alkaline borohydride-released 35S-HS also bound to the FN-C/H II-OA column, and was eluted by 0.29 M NaCl (Fig. 8B) . In contrast, isolated core protein, which had been iodinated and digested by heparitinase enzyme to remove the GAG chains, failed to bind the FN-C/H II-OA column to any t each 1.5 ml fraction. K,. represents the fraction of the inclusion volume relative to the entire inclusion volume of the column. significant extent (Fig. SC) . These results suggest that HSPG binding to IN-C/H II-OA is mediated predominantly by HS.
Neuroblastoma HSPG that had been eluted from an FN-C/H II-OA affinity column was iodinated, subjected to separation by SDS-PAGE, and visualized by autoradiography to identify possible core proteins. A single radioactive band at 78 kDa was observed upon heparitinase digestion (Fig. 9A, lane 2) . This band was not present in undigested samples (Fig. 9A, lane l) , indicating that the 78 kDa band represents the HSPG core protein. Note that the undigested HSPG is apparent at the top of lane 1 (Fig. 9A) . Digestion of the sample with chondroitinase ABC failed to generate the 78 kDa band. Further, digestion of the sample with both chondroitinase and heparitinase resulted in the same 78 kDa band (not shown), demonstrating that the PG is an HSPG without any detectable CS. Under nonreducing conditions, the lZ51-HSPG core protein migrated at a smaller apparent molecular weight of 5 1 kDa (Fig. 9B, lane 2) , suggesting the presence of internal disulfide bonds. In this case, the undigested HSPG, which migrates to the interface of the stacking and running gels, was lost with the stacking gel (Fig. 9B, lane  1) .
Immunoblots of heparitinase-digested lZSI-HSPG demonstrated that the 78 kDa core was recognized by the same anti-HSPG IgGs that disrupted neuroblastoma adhesion and spreading on FN-C/H II, discussed above (Fig. SC, lane 2) . This band was not present in lanes containing the intact HSPG, which had not been digested with heparitinase (Fig. SC, lane l) , or in lanes containing heparitinase enzyme only (not shown). Autoradiography of the immunoblot confirmed that the immunoreactive band was the 78 kDa W-HSPG core protein (Fig. SC, lane 3) . Normal rabbit IgGs failed to recognize the HSPG (not shown).
Anti-HSPG antibodies localize HSPG on the surfaces of neural cells Cell-surface localization of HSPG was demonstrated by immunofluorescence with the polyclonal anti-HSPG IgGs used above. Anti-HSPG IgGs labeled the surface of B 104 neuroblastoma cells, which had been cultured on substrata coated with IN-C/H II-OA, in a punctate manner (Fig. 1OA) . This staining was observed in the absence of permeabilization by detergent, and was localized in a manner characteristic for a cell-surface molecule. In addition, fine granular staining on the substratum near immunoreactive cells was noted, suggesting that these cells may release some of their HSPG into the surrounding microenvironment. Staining of B 104 cells by normal rabbit IgGs was weak and diffuse, and no cell-surface staining was observed (Fig.  10B) .
The anti-HSPG IgGs were also used to determine if primary cells of the nervous system express an immunologically related molecule. In cultures of neonatal rat spinal cord, the most prominent cell-surface staining was noted on spindle-shaped cells (Fig. 11A) . Anti-HSPG IgGs stained the surface of the cell body in a punctate manner, and also stained the process of the cell (Fig. 11 A) . The staining of the cell process was weaker than that of the cell body, but this may reflect the much smaller volume and surface area of the process relative to the cell body. These cells were not stained by antibodies that recognize certain cell- Fraction (B) were dialyzed into binding buffer (see Materials and Methods) and allowed to bind overnight to F'N-C/H II-OA that had been coupled to an Affigel-10 affinity matrix. The column was washed extensively with binding buffer containing 0.2 M NaCl until all unbound 35S counts were removed (20 column ~01s). Bound %-HSPG or %-HS was eluted from the column using a linear salt gradient. ?S counts (solid diamonds) were monitored for each 1 ml fraction, and NaCl concentration (solid line) was determined by conductivity. C, Binding of isolated Y-HSPG core protein to FN-C/H II-OA. HSPG that had previously been eluted from the FN-C/H II-OA affinity column in A was iodinated, and HS was removed by heparitinase digestion. Binding and washing steps were carried out as in A and B. Bound lZ51-HSPG core protein was eluted by 1 M NaCl. I251 counts (solid diamonds) were monitored for each 1 ml fraction. surface markers specific for glia (GFAP and galactocerebroside mainly on the cell body, with less intense staining of the neurites [Raff et al., 1979] ), or neurons (tetanus toxin and neuronal- (Fig. 11B) . No immunoreactivity was noted when rat spinal specific P-tubulin; not shown). Some cells having a neuronal cord cultures were stained with normal rabbit IgGs (not shown). morphology, based on comparison to tetanus toxin-positive Astrocytes from the spinal cord, as identified by anti-GFAP cells, were also stained by anti-HSPG IgGs. This staining was staining (Raff et al., 1979) showed a different pattern of im- (Fig. 11 CD) . In some examples, the extracellular anti-HSPG immunoreactivity appeared to resemble the outline of a cell, and would be consistent with the antigen being deposited at the sites of previous cellmatrix contact (arrows in Fig. 11 C', D) .
In addition to staining cells of the spinal cord, anti-HSPG immunoreactivity was noted on the surface of cells with a Schwann cell morphology in DRG cultures. Anti-HSPG IgGs stained these cells in a bright, punctate manner (Fig. 1 IE) . Staining of these putative Schwann cells was much brighter than that of adjacent fibroblastic cells, although limited cell-surface staining of fibroblastic cells was noted (Fig. 11F) . Our morphological identification of Schwann cells and fibroblasts was consistent with parallel cultures that were stained with an antibody against the S 100 protein, which is found on Schwann cells, but not fibroblasts (Seilheimer and Schachner, 1987 ; not shown).
Discussion
Previous studies had suggested a role for a PG in cellular adhesion, spreading, and neurite outgrowth on the FN-C/H II sequence, found within the C-terminal cell and heparin binding domain of FN (McCarthy et al., 1988; Haugen et al., 1990 Haugen et al., , 1992 . The results presented here further support this idea by demonstrating that neural cell adhesion and spreading on FN-C/H II and the 33/66 kDa C-terminal heparin binding fragments of FN was inhibited by treatment of the cells with heparitinase or anti-HSPG IgGs. Further, we were able to identify an HSPG with a 78 kDa core protein that directly binds to FN-C/H II both in solid phase assays and by affinity chromatography. Anti-HSPG IgGs recognized the 78 kDa core protein and stained the surfaces of neuroblastoma cells and cells from primary neural cultures. Our results identify an HSPG that likely mediates neural cell interactions with a defined sequence in FN, FYI-C/H II.
A similar role for cell-surface PGs in mediating cell adhesion to ECM components, including FN, has been suggested by several investigators (Laterra et al., 1983; Rapraeger and Bernfield, 1983; Koda et al., 1985; Woods et al., 1985 Woods et al., , 1986 LeBaron et al., 1988 LeBaron et al., , 1989 Mugnai et al., 1988; Saunders and Bemfield, 1988; Vallen et al., 1988; Sun et al., 1989) . Our results are consistent with those of others who have also noted that treatment of cells with heparitinase inhibits cell adhesion to FN and heparin binding substrata (Chemoff, 1988; Saunders and Bemfield, 1988) . Specifically regarding the C-terminal cell and heparin binding domain of FN, Mugnai et al. (1988) also demonstrated that heparitinase, but not chondroitinase, inhibits neuroblastoma cell adhesion to this domain of FN, and Saunders and Bemfield (1988) demonstrated that a cell-surface PG can bind directly this FN domain. It is likely that HS mediates most of the binding of the rat neural HSPG to the FN-C/H II sequence, since HS was able to bind to an FN-C/H II affinity column, while isolated HSPG core protein did not. A role for HS-mediated cell adhesion is consistent with previous findings that cell adhesion and neurite outgrowth on FN-C/H II could be inhibited by competition with soluble heparin (Haugen et al., 1990 (Haugen et al., , 1992 . In addition to the data presented here for neural cells, recent evidence points to an HSPG as a mediator of melanoma cell adhesion on the FN-C/H II sequence (Drake et al., 1992) .
In addition to mediating cell adhesion to the FN-C/H II sequence, our data suggest that an HSPG plays a role in the spreading of neuroblastoma cells on the 33/66 kDa heparin binding fragments of FN, which contain the FN-C/H II sequence. Removal of HS by treatment of the cells with heparitinase inhibited the extent of cell spreading on the 33/66 kDa heparin binding fragments. Further, previous results indicated that inhibition of HS binding to the substratum by the addition of soluble heparin also resulted in the same decrease in cell spreading on the 33/ 66 kDa fragments (Haugen et al., 1990) . The presence of multiple adhesion sequences within the 33/66 kDa fragments, including the integrin binding sequences CS 1 and CS5 (Humphries et al., 1987 (Humphries et al., , 1988 Wayner et al., 1989; Guan and Hynes, 1990; Mould et al., 1990, 199 1) and the heparin binding sequences FN-C/H I and FN-C/H II (McCarthy et al., 1988,199O; Haugen et al., 1990) , implies that cell-surface HSPGs may act in combination with integrins to mediate spreading on this region of FN. A coordinate role for integrins and heparin-like molecules in mediating complex cellular responses, including focal adhesion formation (Izzard et al., 1986; Woods et al., 1986) , cell spreading (Asch et al., 1991) , and neurite outgrowth (Mugnai et al., 1988; Haugen et al., 1992) , has been suggested for various ECM components. The immunofluorescence staining of primary cultures of neural cells by anti-HSPG implies that a similar HSPG may play a role in the developing nervous system. Anti-HSPG antibodies stained the surface of various cells from the neonatal rat spinal cord, suggesting that these cells express a molecule that is immunologically related to the HSPG found on rat neuroblastoma cells. This molecule may be important for neuron to substratum interactions by acting as a neuronal cell-surface receptor for heparin binding sequences in FN such as FN-C/H II. Such a model would be consistent with previous data suggesting an important role for a cell-surface PG in spinal cord neurite outgrowth on FN-C/H II (Haugen et al., 1992) . Such a model is also consistent with observations that FN is expressed in limited, but specific, spatial and temporal patterns that are appropriate for a role in neurite outgrowth during CNS development (Stewart and Pearlman, 1987; Chun and Shatz, 1988; Sheppard et al., 1991) . This putative HSPG molecule is likely of importance to glial cells, since astrocytes and Schwann cells were stained by the anti-HSPG antibodies, consistent with the observations of others (Gallo et al., 1987; Carey and Stahl, 1990) . It is possible this molecule also plays a role in glia-substratum or neuron-glia interactions. Ongoing studies should further determine the properties of the molecule immunologically related to the neuroblastoma HSPG, and its role in the interactions of neurons and glia with the ECM.
At present, the identity of the rat neuroblastoma HSPG relative to other known PGs is undetermined. While the rat neuroblastoma HSPG is immunologically related to a mouse melanoma HSPG, to which the antibodies used in this study were generated, the difference in molecular weight between these two HSPGs suggests that they are not identical. It will be important to determine the relationship of the rat neuroblastoma HSPG to the HSPGs previously identified on Schwann cells (Carey and Stahl, 1990 ) and PC12 cells (Matthew et al., 1985) , as well as on other cell types (Saunders et al., 1989; David et al., 1990) . Additionally, several HSPG core proteins have been noted in the nervous system (Hemdon and Lander, 1990) , and it will be important to determine whether the rat neuroblastoma HSPG is related to any of these HSPGs. Regardless of the identity of the rat neuroblastoma HSPG core protein, it is clear that the
